Identification | Back Directory | [Name]
5,6,7,8-Tetrahydro-7-(8-methyl-1-naphthalenyl)-4-[(2R)-2-methyl-1-piperazinyl]-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidine | [CAS]
2847881-42-7 | [Synonyms]
TH-Z816 5,6,7,8-Tetrahydro-7-(8-methyl-1-naphthalenyl)-4-[(2R)-2-methyl-1-piperazinyl]-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidine | [Molecular Formula]
C29H38N6O | [MOL File]
2847881-42-7.mol | [Molecular Weight]
486.65 |
Chemical Properties | Back Directory | [Boiling point ]
709.2±70.0 °C(Predicted) | [density ]
1.168±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [pka]
9.32±0.40(Predicted) |
Hazard Information | Back Directory | [Uses]
TH-Z816 is a reversible inhibitor againstKRAS(G12D)mutation with an IC50 value of 14 μM, which can be used in cancer research[1]. | [References]
[1] Zhongwei Mao, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022 Jan 25;8(1):5. DOI:10.1038/s41421-021-00368-w |
|
|